total
forti
novel
glycyrrhetin
acid
ga
deriv
design
synthes
cytotox
activ
novel
compound
test
two
human
breast
cancer
cell
line
vitro
mtt
method
evalu
result
reveal
comparison
ga
compound
show
promis
anticanc
activ
ic
respect
merit
explor
new
anticanc
agent
breast
cancer
one
common
diseas
amongst
women
throughout
world
women
lost
live
develop
countri
develop
countri
new
breast
cancer
case
breast
cancer
death
project
occur
unit
state
current
hot
research
topic
develop
novel
therapeut
improv
select
higher
anticanc
activ
chemic
modif
natur
sourc
larg
number
chemotherapeut
agent
deriv
natur
product
use
treatment
cancer
shown
satisfactori
therapeut
effect
like
vinblastin
vincristin
camptothecin
deriv
eg
topotecan
irinotecan
etoposid
deriv
epipodophyllotoxin
paclitaxel
terpenoid
largest
group
natur
compound
found
plant
among
terpenoid
larg
number
triterpenoid
exhibit
cytotox
varieti
tumor
cell
well
anticanc
efficaci
preclin
anim
model
triterpenoid
regul
tumor
cell
prolifer
transform
surviv
invas
angiogenesi
metastasi
chemoresist
radioresist
kind
triterpenoid
glycyrrhetin
acid
ga
mani
valuabl
pharmacolog
properti
antivir
antiallerg
antiinflammatori
antiulc
anticanc
activ
report
ga
exhibit
select
toxic
varieti
tumor
cell
make
ideal
lead
compound
anticanc
treatment
ferul
acid
natur
product
also
appar
biolog
activ
like
antibacteri
antiinflammatori
anticanc
properti
improv
cytotox
ga
mani
research
tri
enhanc
potenc
variou
derivat
studi
shown
addit
lipophil
fragment
antitumor
molecul
could
increas
anticanc
activ
addit
natur
product
conjug
amino
acid
provid
improv
bioacit
studi
base
prodrug
principl
previous
report
therapeut
potenti
ga
design
synthes
seri
novel
ga
deriv
group
coupl
lipophil
fragment
ferul
acid
analog
group
coupl
amino
acid
lmethionin
lselenomethionin
improv
anticanc
potenc
ga
total
forti
deriv
ga
success
synthes
structur
character
hnmr
cnmr
ms
element
analysi
vitro
anticanc
activ
test
use
mtt
assay
two
human
breast
cancer
cell
line
one
normal
human
retin
pigment
epitheli
cell
line
deriv
exhibit
much
stronger
inhibitori
activ
ga
two
breast
cancer
cell
line
lower
posit
control
doxorubicin
rel
lower
inhibitori
activ
normal
cell
importantli
one
deriv
compound
see
section
show
significantli
stronger
cytotox
cell
cell
ga
data
suggest
coupl
lipophil
fragment
especi
ferul
acid
methyl
ester
amino
acid
especi
lselenomethionin
ga
promis
approach
gener
highli
activ
anticanc
compound
sar
develop
progress
discov
potenti
lead
antitumor
drug
synthesi
new
ga
deriv
carri
accord
step
shown
scheme
molecul
design
synthes
seri
novel
ga
deriv
group
coupl
lipophil
fragment
ferul
acid
analog
group
coupl
amino
acid
lmethionin
lselenomethionin
improv
anticanc
potenc
ga
total
forti
deriv
ga
success
synthes
structur
character
hnmr
cnmr
ms
element
analysi
vitro
anticanc
activ
test
use
mtt
assay
two
human
breast
cancer
cell
line
one
normal
human
retin
pigment
epitheli
cell
line
deriv
exhibit
much
stronger
inhibitori
activ
ga
two
breast
cancer
cell
line
lower
posit
control
doxorubicin
rel
lower
inhibitori
activ
normal
cell
importantli
one
deriv
compound
see
section
show
significantli
stronger
cytotox
cell
cell
ga
data
suggest
coupl
lipophil
fragment
especi
ferul
acid
methyl
ester
amino
acid
especi
lselenomethionin
ga
promis
approach
gener
highli
activ
anticanc
compound
sar
develop
progress
discov
potenti
lead
antitumor
drug
synthesi
new
ga
deriv
carri
accord
step
shown
scheme
deriv
new
compound
previous
report
lipophil
fragment
obtain
treatment
methanol
ethanol
catalyz
concentr
sulfur
acid
avoid
format
byproduct
use
tbutyloxycarbonyl
boc
group
protect
amino
acid
thu
obtain
compound
use
next
step
without
purif
compound
obtain
format
ester
bond
compound
ga
stir
h
room
temperatur
dri
dichloromethan
dcm
catalyz
hydrochlorid
edci
dmap
appli
method
introduc
nboc
group
protect
amino
acid
posit
obtain
compound
get
compound
deprotect
perform
treat
compound
dri
hcl
ga
dcm
anticanc
activ
compound
cell
determin
vitro
mtt
assay
doxorubicin
includ
experi
posit
control
ic
ga
also
present
compar
anticanc
activ
data
calcul
present
ic
valu
valu
given
deviat
ic
drug
concentr
effect
inhibit
cell
growth
measur
mtt
method
b
drug
doxorubicin
adr
use
posit
control
studi
addit
observ
introduct
differ
lipophil
fragment
group
differ
amino
acid
group
ga
result
indiffer
cytotox
combin
ferul
acid
methyl
ester
analog
cytotox
higher
correspond
ethyl
ester
analog
ic
valu
also
found
lipophil
fragment
methoxi
group
higher
anticanc
activ
ic
valu
meanwhil
introduct
lselenomethionin
posit
compound
lead
lower
ic
valu
lmethionin
compound
almost
new
synthet
ga
deriv
exhibit
much
stronger
inhibitori
activ
cell
rel
lower
inhibitori
activ
cell
ga
chemic
reagent
commerci
avail
use
without
purif
routin
thinlay
chromatographi
tlc
perform
silica
gel
plate
silica
gel
qingdao
haiyang
chemic
co
ltd
qingdao
china
visual
perform
use
uv
hnmr
cnmr
spectra
record
instrument
bruker
billerica
usa
room
temperatur
tm
intern
standard
cdcl
dmsod
solvent
chemic
shift
express
ppm
coupl
constant
j
hz
mass
spectra
record
msq
plu
mass
spectromet
thermo
scientif
waltham
usa
melt
point
measur
micro
melt
point
apparatu
shanghai
precis
scientif
instrument
co
ltd
shanghai
china
uncorrect
ferul
acid
acid
isoferul
acid
acid
five
drop
h
reflux
methanol
ethanol
h
reaction
mixtur
concentr
vacuo
residu
dissolv
ethyl
acet
organ
layer
wash
aqueou
nahco
solut
water
dri
anhydr
na
ethyl
acet
remov
vacuo
residu
purifi
column
chromatographi
silica
gel
use
ethyl
acetatepetroleum
ether
mixtur
eluent
afford
compound
appropri
amino
acid
equiv
sodium
bicarbon
equiv
dissolv
mixtur
water
ditertbutyl
dicarbon
equiv
ad
mixtur
stir
room
temperatur
h
remov
reduc
pressur
mixtur
extract
ethyl
acet
solut
acidifi
use
hydrochlor
acid
solut
extract
three
time
ethyl
acet
combin
organ
layer
wash
brine
dri
sodium
sulfat
filter
solvent
evapor
crude
protect
amino
acid
use
without
purif
ga
mg
mmol
dissolv
dri
dcm
ml
stir
room
temperatur
min
edci
mg
mmol
dmap
mg
mmol
compound
mmol
ad
solut
reaction
mixtur
stir
room
temperatur
h
organ
layer
wash
hcl
solut
concentr
vacuo
residu
purifi
column
chromatographi
silica
gel
ethyl
acetatepetroleum
eluent
yield
pure
compound
ferul
acid
methyl
ester
ferul
acid
ethyl
ester
acid
methyl
ester
isoferul
acid
methyl
ester
compound
obtain
ga
isoferul
acid
methyl
ester
white
solid
mg
isoferul
acid
ethyl
ester
protect
amino
acid
nboclmethionin
nboclselenomethionin
mmol
dissolv
dri
dcm
stir
min
edci
mg
mmol
dmap
mg
mmol
ad
solut
mixtur
stir
h
appropri
ga
deriv
mmol
ad
mixtur
stir
anoth
h
reaction
mixtur
stir
room
temperatur
h
organ
layer
wash
hcl
solut
concentr
vacuo
residu
purifi
column
chromatographi
silica
gel
ethyl
acetatepetroleum
yield
pure
compound
sch
dd
j
hz
sch
ddd
j
hz
cooch
dd
j
hz
j
hz
chcoo
j
tran
hz
j
hz
j
hz
j
tran
hz
na
anal
calcd
c
h
c
h
n
found
c
h
n
dd
j
hz
ddd
j
hz
sech
dd
j
hz
sech
ddd
j
hz
cooch
och
dd
j
hz
j
hz
chcoo
j
tran
hz
j
hz
j
hz
dd
j
hz
j
tran
hz
na
anal
calcd
c
h
se
c
h
n
found
c
h
n
isoferul
acid
ethyl
ester
boclmethionin
obtain
nboclmethionin
colourless
powder
mg
mp
hnmr
cdcl
j
hz
ch
bocch
dd
j
hz
ddd
j
hz
sch
dd
j
hz
sch
ddd
j
hz
och
q
j
hz
ch
ch
dd
j
hz
j
hz
chcoo
j
tran
hz
j
hz
j
hz
dd
j
hz
j
tran
hz
cnmr
cdcl
result
demonstr
compound
could
potenti
antitumor
agent
deserv
research
sar
studi
disclos
incorpor
lipophil
fragment
amino
acid
group
anticanc
natur
product
could
increas
activ
compar
parent
compound
studi
area
progress
laboratori
report
futur
